Q3 Earnings Forecast for Geron Issued By Leerink Partnrs

Key Points

• Leerink Partners projects that Geron Corporation will report earnings per share of ($0.01) for Q3 2026, with a full-year consensus estimate of ($0.25).
• Goldman Sachs initiated coverage of Geron with a sell rating and a price target of $1.00, while Scotiabank downgraded its target from $4.00 to $1.50.
• Geron reported a significant year-over-year revenue increase of 5455.6%, with a quarterly revenue of $49.04 million, surpassing analysts' expectations.

Geron Corporation (NASDAQ:GERN - Free Report) - Analysts at Leerink Partnrs issued their Q3 2026 EPS estimates for Geron in a research note issued to investors on Tuesday, August 12th. Leerink Partnrs analyst F. Khurshid anticipates that the biopharmaceutical company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Geron's current full-year earnings is ($0.25) per share.

Geron (NASDAQ:GERN - Get Free Report) last released its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The business had revenue of $49.04 million during the quarter, compared to analysts' expectations of $47.30 million. Geron had a negative net margin of 53.52% and a negative return on equity of 31.37%. The company's quarterly revenue was up 5455.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.10) earnings per share.

GERN has been the subject of a number of other research reports. Scotiabank cut shares of Geron from a "sector outperform" rating to a "sector perform" rating and cut their target price for the stock from $4.00 to $1.50 in a research note on Thursday, May 8th. The Goldman Sachs Group started coverage on shares of Geron in a research report on Thursday, July 10th. They set a "sell" rating and a $1.00 price target on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $4.19.

Geron Price Performance

Shares of GERN stock traded down $0.01 on Wednesday, reaching $1.44. 17,874,503 shares of the company were exchanged, compared to its average volume of 12,795,693. The company has a market cap of $918.74 million, a price-to-earnings ratio of -11.08 and a beta of 0.73. The business has a 50-day moving average price of $1.38 and a 200 day moving average price of $1.60. The company has a debt-to-equity ratio of 0.46, a quick ratio of 6.79 and a current ratio of 7.87. Geron has a 1 year low of $1.09 and a 1 year high of $4.83.

Hedge Funds Weigh In On Geron

Several institutional investors and hedge funds have recently bought and sold shares of GERN. Frisch Financial Group Inc. boosted its holdings in Geron by 84.3% in the 1st quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 8,700 shares during the last quarter. StoneCrest Wealth Management Inc. acquired a new position in Geron in the 2nd quarter valued at about $35,000. Integrated Wealth Concepts LLC acquired a new position in Geron in the 4th quarter valued at about $36,000. Savant Capital LLC boosted its holdings in Geron by 73.8% in the 2nd quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company's stock valued at $37,000 after purchasing an additional 11,074 shares during the last quarter. Finally, Summit Financial Strategies Inc. acquired a new position in Geron in the 2nd quarter valued at about $38,000. 73.71% of the stock is currently owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.